

Comprehensive Alcohol and Drug Treatment Program

Disclosure

Professional Services Group, Kenosha County Division of Health, Kenosha County Detention Center, and the Department of Corrections do not have any relevant financial relationships with any commercial interests

Objectives

- ▶ CADTP Overview
- ▶ CADTP Program Components
- ▶ Process of injectable Naltrexone
- ▶ KCDOH Assessment
- ▶ CADTP Program Data
- ▶ CADTP Program Outcomes

Program Overview

- ▶ Target Population
 - ▶ Opiate and/or alcohol addiction, Criminal History related to use, many have a mental health history
- ▶ Referral Process
 - ▶ Referrals from any community agency as well as individuals
- ▶ Major Referral Sources
 - ▶ KCDC, KHDS, DOC
- ▶ Intake/Assessment Process
 - ▶ Recovery Specialist

Program Components


- ▶ AODA/MH Treatment - Program Therapist
 - ▶ Weekly individual and group treatment with licensed therapist
- ▶ Intensive Case Management - 2 Recovery Specialists
 - ▶ Recovery Specialist assistance with housing, employment, transportation, health insurance access and coordination of services
- ▶ Medication Management
 - ▶ Prescription for Vivitrol and other medications
- ▶ Health Services
 - ▶ Labs, drug screens, health screen and injections

What is injectable Naltrexone?

- ▶ Injectable Naltrexone is a long acting injection, which means it only has to be administered once a month or every 28 days
- ▶ Injectable Naltrexone is NOT a standalone treatment method and should be combined with an alcohol or recovery treatment program
- ▶ Indications for injectable Naltrexone
 - ▶ Treating alcohol dependence. Client should stop drinking alcohol prior to injectable Naltrexone therapy.
 - ▶ Preventing relapse to opioid dependence AFTER opioid detox. Prior to receiving injection, client **MUST BE** opioid-free for a minimum of 7-10 days to avoid sudden withdrawal.
- ▶ Contraindications for injectable Naltrexone
 - ▶ If still actively using or currently in withdrawal
 - ▶ If pregnant or breastfeeding
 - ▶ If allergic to Naltrexone

How does injectable Naltrexone work?

- ▶ Injectable Naltrexone is an opioid blocker.
- ▶ Blocks the effects of opioids in the brain's reward system.
 - ▶ Blocks those pleasurable or euphoric feeling that can often lead to addiction



Kenosha Co Division of Health: Assessment

- ▶ Receive referral from PSG
- ▶ Assessment
 - ▶ Include synopsis of program
 - ▶ Consents—KCDOH Authorization for Disclosure, HIPPA, Medical procedure
 - ▶ Health History Questionnaire—Discusses past/current history of substance use; Overdoses (Naloxone utilized?); Social support ; Plan for treatment
 - ▶ Initial lab work—CMP (LFT's), CBC, HIV, Syphilis, Hep B & C, CT/GC) and urine analysis
- ▶ Review of Multidimensional Assessment (MDA) and Lab results
 - ▶ KCDC—Once release date determined, client released from KCDC and presents directly to clinic to receive first injection
 - ▶ DDC—Last date of usage determined, client released from KARE center and presents directly to clinic to receive first injection
 - ▶ Community—Injection date determined with assistance of facilitator

Injection Appointment

- ▶ Present to clinic at scheduled date and time
- ▶ Upon presentation, urine provided
 - ▶ 12 panel and ETOH screen completed; if female, pregnancy test
- ▶ Naltrexone challenge initiated (25mg tablet)
- ▶ Health History Questionnaire completed
- ▶ MAT consent reviewed and signed by client
 - ▶ 1st injection appointment—client receives Vivitrol brochure, emergency pain management card, appointment card, bracelet, and dog tag
- ▶ Once naltrexone challenge determined to be negative, injection given.
- ▶ Follow up appointment scheduled for lab work and/or next injection
 - ▶ Lab work—completed 1, 3, 6, 9, and 12 months
 - ▶ Injection scheduled every 28 days

Common Side Effects of injectable Naltrexone Treatment

- ▶ Nausea
- ▶ Tiredness or fatigue
- ▶ Headache
- ▶ Dizziness
- ▶ Decreased appetite
- ▶ Painful joints
- ▶ Muscle cramps
- ▶ Cold symptoms
- ▶ Trouble sleeping
- ▶ Toothache

Severe Side Effects of injectable Naltrexone Treatment

- ▶ Injection site
 - ▶ Intense pain
 - ▶ Tissue that feels hard
 - ▶ Swelling
 - ▶ Lumps
 - ▶ Blisters
 - ▶ Open wound
 - ▶ Dark scab
- ▶ Sudden opioid withdrawal
- ▶ Liver damage
- ▶ Depressed mood
 - ▶ Suicidal thoughts or ideations
- ▶ Eosinophilic pneumonia
- ▶ Anaphylaxis

Program Data

- ▶ 232 referrals
- ▶ 121 clients provided services by PSG
- ▶ 106 clients provided services by Health
- ▶ 102 Multi-Dimensional Assessments by PSG licensed therapist
- ▶ 79 clients received injections through June 30, 2017.
- ▶ Male - 69% Female - 31%
- ▶ Average age - 38 years old
- ▶ Addiction History - 11 years of opiate use and 20 years of alcohol use
- ▶ 75% of participants have a mental health history or diagnosis

Program Measures and Outcomes

- ▶ 94% of participants report(ed) significant reductions in cravings (at least 50%).
- ▶ 88% have or gained stable housing.
- ▶ 82% are employed or were employed at discharge.
- ▶ 93% have not recidivated.
- ▶ Of the 274 drug screens performed by Health/PSG post initial injection only 9 have been positive for opiates and 11 positive for alcohol (less than 5%).